

06/19/01



JC961 U.S. PTO

06-20-01



27123

PATENT TRADEMARK OFFICE

A

Docket No. 4274-4000
Express Mail No. EL762623628US

↑ AFFIX CUSTOMER NO. LABEL

↑
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

UTILITY APPLICATION AND FEE TRANSMITTAL §(1.53(b))

J1036 U.S. PTO
09/884526
06/19/01

Commissioner for Patents
BOX PATENT APPLICATION
Washington, D.C. 20231

Sir:

Transmitted herewith for filing is the patent application of

Inventor(s) names and addresses:

- (1) David Meeker
93 rue Jouffroy
Paris 75017 France

- (2) Seng H. Cheng
50 Wall Street
Wellesley, Massachusetts 02481

☐ Additional inventors are listed on a separate sheet

For: COMBINATION ENZYME REPLACEMENT, GENE THERAPY AND SMALL
MOLECULE THERAPY FOR LYSOSOMAL STORAGE DISEASES

Enclosed Are:

- 40 page(s) of specification
- 1 page(s) of Abstract
- 2 page(s) of claims
- 2 sheets of ☒ Formal ☐ Informal drawings
- 6 page(s) of Declaration and Power of Attorney

- ☒ Unsigned
- ☐ Newly Executed
- ☐ Copy from prior application
- ☐ Deletion of inventors including Signed Statement under 37 C.F.R. §1.63(d)(2)

☐ **REQUEST AND CERTIFICATION UNDER 35 U.S.C. §122(b)(2)(B)(i) (form PTO/SB/35)**

As indicated on the attached Request and Certification, Applicant(s) certify that the invention disclosed in the attached application HAS NOT and WILL NOT be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. Applicant(s) therefore request(s) that the attached application NOT be published under 35 U.S.C. §122(b).

☒ Incorporation by Reference:

☒ The entire disclosure of the prior provisional application, Serial No. 60/212,377 filed June 19, 2000, is considered as being part of the disclosure of the accompanying application and is incorporated herein by reference.

☐ Deletion of Inventors (37 C.F.R. §1.63(d) and §1.33(b))

Signed statement attached deleting inventor(s) named in the prior application serial no. _____, filed _____.

☐ Microfiche Computer Program (Appendix)

☐ page(s) of Sequence Listing

☐ computer readable disk containing Sequence Listing

☐ Statement under 37 C.F.R. §1.821(f) that computer and paper copies of the Sequence Listing are the same

☒ Assignment Papers (assignment cover sheet and assignment documents)

☐ A check in the amount of \$40.00 for recording the Assignment

☐ Charge the Assignment Recordation Fee to Deposit Account No. 13-4500, Order No. _____.

☒ Assignment Papers filed in the provisional application Serial No. 60/212,377

☐ Certification of chain of title pursuant to 37 C.F.R. §3.73(b)

☐ Priority is claimed under 35 U.S.C. §119 for:
Application No(s). __, filed __, in __ (country).

☐ Certified Copy of Priority Document(s) [_____]

☐ filed herewith

☐ filed in application Serial No. _____, filed _____.

☐ English translation document(s) [_____]

☐ filed herewith

☐ filed in application Serial No. _____, filed _____.

☒ Priority is claimed under 35 U.S.C. §119(e) for:
Provisional Application No. 60/212,377, filed June 19, 2000.

- ☐ Information Disclosure Statement
- ☐ Copy of [_____] cited references
- ☐ PTO Form-1449
- ☐ References cited in parent application Serial No. _____, filed _____.
- ☐ Related Case Statement under 37 C.F.R. §1.98(a)(2)(iii)
- ☐ A copy of related pending U.S. Application(s) Serial No(s): _____, filed _____, respectively, is attached hereto.
- ☐ A copy of related pending U.S. Application(s) entitled, _____, filed _____ to inventor(s) _____, respectively, is attached hereto.
- ☐ A copy of each related application(s) was submitted in parent application serial no. _____, filed _____.
- ☐ Preliminary Amendment
- ☒ Return receipt postcard (MPEP 503)
- ☐ This is a ☐ continuation ☐ divisional ☐ continuation-in-part of prior application serial no. _____, filed _____, to which priority under 35 U.S.C. §120 is claimed.
- ☐ Cancel in this application original claims _____ of the parent application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
- ☐ A Preliminary Amendment is enclosed. (Claims added by this Amendment have been properly numbered consecutively beginning with the number following the highest numbered original claim in the prior application).
- ☐ The status of the parent application is as follows:
- ☐ A Petition for Extension of Time and a Fee therefor has been or is being filed in the parent application to extend the term for action in the parent application until _____.
- ☐ A copy of the Petition for Extension of Time in the co-pending parent application is attached.
- ☐ No Petition for Extension of Time and Fee therefor are necessary in the co-pending parent application.
- ☐ Please abandon the parent application at a time while the parent application is pending or at a time when the petition for extension of time in that application is granted and while this application is pending has been granted a filing date, so as to make this application co-pending.
- ☐ Transfer the drawing(s) from the parent application to this application
- ☐ Amend the specification by inserting before the first line the sentence:
This is a ☐ continuation ☐ divisional ☐ continuation-in-part of co-pending application Serial No. _____, filed _____.


I. CALCULATION OF APPLICATION FEE				
	Number Filed	Number Extra	Rate	Basic Fee \$710.00/355.00
Total Claims	11- 20 =	0x	\$18.00/ \$9.00	\$ 0
Independent Claims	1- 3 =	0x	\$80.00/ \$40.00	\$ 0
<input type="checkbox"/> Multiple Dependent Claims		If marked, add fee of \$270.00 (\$135.00)		\$ 0
TOTAL:				\$ 710.00

- ☐ Small entity status is or has been claimed. Reduced fees under 37 C.F.R. §1.9 (f) paid herewith \$_____.
- ☐ A check in the amount of \$_____ in payment of the application filing fees is attached.
- ☒ Charge fee to Deposit Account No. 13-4500, Order No. 4274-4000. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required for filing this application pursuant to 37 CFR §1.16, **including all extension of time fees pursuant to 37 C.F.R. § 1.17 for maintaining copendency** with the parent application, or credit any overpayment to Deposit Account No. 13-4500, Order No. 4274-4000. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated: June 19, 2001

By:


Kenneth H. Sonnenfeld
Registration No. 33,285

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): DAVID MEEKER, ET AL.

Group Art Unit: To Be As signed

Serial No.: To be Assigned

Examiner: To be Assigned

Filed: June 19, 2001

For: COMBINATION ENZYME REPLACEMENT, GENE THERAPY AND SMALL
MOLECULE THERAPY FOR LYSOSOMAL STORAGE DISEASES

EXPRESS MAIL CERTIFICATE

Express Mail Label No.: EI 762623628US

Date of Deposit: June 19, 2001

I hereby certify that the following attached paper(s) and/or fee

1. UTILITY APPLICATION AND FEE TRANSMITTAL §(1.53(B))
(4 pages – in duplicate)
2. SPECIFICATION (40 pages); ABSTRACT (1 page); CLAIMS
(2 pages)
3. FORMAL DRAWINGS - FIGURES 1A-1B (2 Sheets)
4. COMBINED DECLARATION AND POWER OF ATTORNEY
(6 pages - Unexecuted)
5. RETURN RECEIPT POSTCARD

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Kenneth H. Sonnenfeld

(Typed or printed name of person mailing papers(s) and/or fee)


(Signature of person mailing paper(s) and/or fee)

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile